Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ATXS
- Price
- 12.58
- Stock movement up
- +0.08 (0.64%)
- Company name
- Astria Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 718.13M
- Ent value
- 660.46M
- Price/Sales
- 1017.18
- Price/Book
- 3.08
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -34.65%
- 1 year return (CAGR)
- 66.18%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
DIVIDENDS
ATXS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1017.18 |
| Price to Book | 3.08 |
| EV to Sales | 935.50 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 57.08M |
| EPS (TTM) | -2.14 |
| FCF per share (TTM) | -2.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 706.00K |
| Gross profit (TTM) | 706.00K |
| Operating income (TTM) | -136.51M |
| Net income (TTM) | -124.03M |
| EPS (TTM) | -2.14 |
| EPS (1y forward) | -2.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -19335.69% |
| Profit margin (TTM) | -17567.99% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 96.28M |
| Net receivables | 17.24M |
| Total current assets | 253.55M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.25M |
| Total assets | 271.87M |
| Accounts payable | 1.14M |
| Short/Current long term debt | 4.46M |
| Total current liabilities | 23.52M |
| Total liabilities | 38.61M |
| Shareholder's equity | 233.25M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -119.73M |
| Capital expenditures (TTM) | 32.88M |
| Free cash flow (TTM) | -152.62M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -53.17% |
| Return on Assets | -45.62% |
| Return on Invested Capital | -52.86% |
| Cash Return on Invested Capital | -65.04% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.48 |
| Daily high | 12.59 |
| Daily low | 12.45 |
| Daily Volume | 3.15M |
| All-time high | 52200.00 |
| 1y analyst estimate | 24.60 |
| Beta | 0.08 |
| EPS (TTM) | -2.14 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 5 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ATXS | S&P500 | |
| Current price drop from All-time high | -99.98% | -0.89% |
| Highest price drop | -99.99% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -99.98% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
COMPANY DETAILS
Marketcap
718.13M
Marketcap category
Small-cap
Description
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Employees
78
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner